Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

PURPOSE: This study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors. METHODS: Patients were enrolled into 1 of 3 dose cohorts (6, 12, or 20 mg/kg) of single-agent ganitumab administered intravenously every 2 weeks. Dose-limiting toxicity (D...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Murakami, Haruyasu, Doi, Toshihiko, Yamamoto, Nobuyuki, Watanabe, Junichiro, Boku, Narikazu, Fuse, Nozomu, Yoshino, Takayuki, Ohtsu, Atsushi, Otani, Satoru, Shibayama, Kazuhiro, Takubo, Takatoshi, Loh, Elwyn
Format: Artigo
Langue:Inglês
Publié: Springer-Verlag 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3428530/
https://ncbi.nlm.nih.gov/pubmed/22810805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1924-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires